Rapport Therapeutics Reports $56.6M Net Loss and First Revenue Recognition in Latest 10-Q Filing

Rapport Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $56.6 million for the quarter, compared to a loss of $26.7 million in the same period last year. For the six months ended June 30, 2026, the net loss was $76.5 million, up from $50.8 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which surged to $51.4 million for the quarter, a 128% increase from $22.7 million in the previous year. This rise reflects the company's ongoing clinical trials, particularly for its lead product candidate, RAP-219, which is being developed for drug-resistant focal onset seizures.

In terms of revenue, Rapport Therapeutics recognized $20 million in collaboration revenue during the first half of 2026, stemming from a non-refundable upfront payment received under its license agreement with Tenacia Biotechnology. This marks the company's first revenue recognition, as it had no collaboration revenue in the prior year. The company’s total operating expenses for the six months ended June 30, 2026, reached $105 million, significantly higher than the $56.6 million reported for the same period in 2025. The increase in expenses is largely due to the ramp-up of clinical trial activities and personnel-related costs.

Operationally, Rapport Therapeutics is advancing its clinical programs, particularly for RAP-219, which has shown promising results in Phase 2a trials. The company is now preparing for Phase 3 trials and has initiated an open-label long-term safety trial for RAP-219. The company also plans to expand its epilepsy portfolio to include primary generalized tonic-clonic seizures and is exploring the potential of RAP-219 in treating bipolar disorder. As of June 30, 2026, the company had cash, cash equivalents, and short-term investments totaling $436.1 million, which it believes will fund operations into the second half of 2029.

The company has also made strategic moves, including the execution of the Tenacia License Agreement, which grants exclusive rights for the development and commercialization of RAP-219 in specific territories. This agreement is expected to provide additional funding through milestone payments and royalties, contingent on the successful commercialization of the product. However, the company acknowledges the need for further financing to support its ongoing operations and product development, as it continues to incur significant losses and has not yet achieved profitability.

Looking ahead, Rapport Therapeutics anticipates that its expenses will continue to rise as it advances its clinical trials and expands its research efforts. The company remains focused on securing additional funding through equity offerings, collaborations, and other capital sources to sustain its growth and development initiatives.